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Acute Stroke Treatment
Carotid “Stenters” to the Rescue*
Christopher J. White, MD
New Orleans, Louisiana
Acute ischemic stroke is a devastating illness that will affect
three-quarters of a million Americans this year (1). Not only
is stroke one of the leading causes of death, it is our leading
cause of adult disability (2). Similar to acute myocardial
infarction, the primary treatment goal for stroke is early
reperfusion to prevent or minimize injury. Unfortunately,
American medicine has failed to make “on-demand” (24
h/day, 7 days a week, 365 days a year) reperfusion therapy as
accessible for stroke as it has for heart attacks. Without a
national mandate for “90-min door-to-balloon time,” stroke
has been left behind. Our failure to offer timely on-demand
access to stroke reperfusion therapy is a national healthcare
embarrassment—an “elephant in the room” that no one is
talking about. The only way to let this elephant out of the
room is to remove the barriers to on-demand stroke reper-
fusion therapy.
See page 2363
In 1996, the U.S. Food and Drug Agency (FDA)
approved intravenous (IV) tissue plasminogen activator
(t-PA) for acute stroke, but only if administered within 3 h
fter onset to patients without contraindications (3,4).
oday, 15 years later, IV t-PA remains the only approved
herapy for acute stroke, with a recent guideline update
xtending the treatment time from 3 h to 4.5 h for a selected
roup of low-risk patients (5). Amazingly, despite FDA
pproval, IV thrombolysis is infrequently used for ischemic
troke patients with2% of patients (1 in 50) so treated (6).
lthough rapid initiation of IV t-PA with a “door-to-
eedle time” of 60 min is important for a good outcome,
he American Heart Association Get With The Guidelines–
troke national registry recently reported that less than
ne-third of stroke patients treated with IV t-PA are treated
n 60 min of arrival at the hospital (7).
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ith IV t-PA are because: 1) they present too late (3 to
.5 h) after the onset of symptoms for IV t-PA; or 2) they
re poor candidates for IV t-PA. The good news is that
any of these patients can still receive catheter-based
eperfusion therapy if an interventional stroke team is
vailable (8 –10). The bad news is that, due to manpower
hortages of specialized stroke physicians, there are few
ospitals that offer on-demand, catheter-based stroke
herapy.
Barriers to providing on-demand stroke reperfusion ther-
py are largely related to shortages of stroke specialty
hysicians. In contrast, manpower has not been a barrier to
roviding timely reperfusion therapy for ST-segment eleva-
ion myocardial infarction (STEMI) patients. The national
tandard for STEMI care is a 90-min door-to-balloon time,
ith cardiologists and cardiac catheterization laboratories
vailable 24 h/day, 7 days a week, 365 days a year to provide
mergency on-demand reperfusion therapy. This quality
andate is reinforced by Medicare’s publicly reported Core
easures that specifically report individual hospital’s door-
o-balloon times.
A shortfall of stroke specialty physicians may explain the
iscrepancy between on-demand reperfusion therapy for
TEMI patients compared with ischemic stroke patients.
here are not enough stroke neurologists—physicians who
re skilled in diagnosing and prescribing treatment for
troke patients for every hospital emergency department to
ave one on call at every hospital that treats stroke patients.
ne way to lessen the impact of the limited number of
troke neurologists is to use telemedicine. With an effective
elemedicine program, a single stroke neurologist can sup-
ort acute stroke care in multiple remote hospitals (11).
There is also a shortage of interventional neuroradiolo-
ists (i.e., physicians skilled in intracranial catheter-based
herapies). Traditionally, these physicians have been ex-
ected to provide on-demand catheter-based stroke reper-
usion therapy. However, according to 1 report, there are 5
.S. states without a neuroradiologist (12). There are not
nough neuroradiologists for every hospital treating strokes
o have sufficient manpower available for on-demand
atheter-based reperfusion therapy. Because of the need for
round-the-clock stroke coverage, the on-call obligations
an become quite burdensome, and for that reason, they
ay choose not to participate in acute stroke therapy.
What can be done to increase the number of interven-
ional stroke physicians capable of providing on-demand
troke reperfusion therapy? Papanagiotou et al. (13), in this
ssue of the Journal, address the need for additional man-
ower among interventionalists by including physicians
erforming carotid artery stenting (CAS). The authors
emonstrated the effectiveness of CAS for a high-risk
ubgroup of acute stroke patients, including those with
arge-vessel, extracranial carotid artery occlusions. These
arge-vessel strokes respond poorly to IV t-PA and carry a
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authors found that CAS was able to successfully recanalize
95% (21 of 22) of extracranial carotid occlusions with few
procedural complications and with good outcomes in 50%
of these very sick patients at follow-up. These data confirm
2 other smaller series reporting encouraging results for
urgent stroke reperfusion therapy with carotid stents
(14,15).
Acute carotid artery occlusive disease causes devastating
strokes that do not respond well to IV t-PA, but are
amenable to catheter-based therapy with CAS. This invites
a larger pool of CAS-capable physicians including cardiol-
ogists, radiologists, vascular surgeons, neurosurgeons, and
interventional neurologists to join stroke teams (10,16,17).
Most of these CAS-capable physicians have not tradition-
ally been included on stroke teams, but including them
would spread the on-call stroke coverage over a larger
number of providers and improve access to on-demand
stroke therapy.
Rather than continuing to fight “turf wars” between
specialties, it is time for interventionalists to work together
on multispecialty stroke teams led by stroke neurologists
(18). American medicine cannot afford to allow political
infighting to constrain the number of willing intervention-
alists from participating in acute stroke care. We can
improve access to on-demand stroke therapy with telemedi-
cine systems that allow a stroke neurologist to participate in
the care of stroke patients at multiple sites, and we can
dramatically increase stroke interventionalists by recruiting
CAS-capable providers to the stroke team. The time has
come for a patient-focused national quality mandate to
improve on-demand access to stroke reperfusion therapy.
We did it for heart attacks. Now we need to do it for
strokes.
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